HER2-Directed Therapies in NSCLC: Navigating Clinical Insights, Integration Challenges, and Access Considerations
Experts examine the evolving landscape of HER2-directed therapies in non–small cell lung cancer (NSCLC), discussing their efficacy, safety, and integration into clinical practice, while considering emerging treatments, patient selection criteria, real-world outcomes, and strategies to balance access, cost, and value in managed care settings.
Episodes
September 30th 2024EP. 1: Introduction and Current Landscape of HER2 in NSCLC
Panelists discuss how HER2-directed therapies in non–small cell lung cancer (NSCLC) are evolving, with experts examining the distinction between HER2 mutation and expression, evaluating the efficacy and safety of current treatments like trastuzumab deruxtecan and ado-trastuzumab emtansine, and considering their potential to reshape treatment approaches as recommended in NCCN guidelines.
September 30th 2024EP. 2: Safety and Efficacy of HER2-Directed ADCs for NSCLC
Panelists discuss how the selection between fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine is guided by findings from pivotal trials like DESTINY-Lung01 and DESTINY-Lung02, real-world patient outcomes compared with clinical trial results, and the management of common treatment-related adverse events associated with these HER2-directed therapies.
